Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 4,234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

NCT06980948
View directory record Official record
Conditions
Chronic Neuropathic Pain
Interventions
ST-503, Sham (No Treatment)
Genetic · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

NCT04909450
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
45
States / cities
Cave Creek, Arizona • Loma Linda, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Active, not recruiting Phase 1 Interventional

Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH.

NCT07751120
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal

NCT00851747
View directory record Official record
Conditions
Obesity
Interventions
Phosphatidylcholine Deoxycholate, Saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RhinAer Procedure for Treatment of Chronic Rhinitis Study

NCT04533438
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
RhinAer Stylus, Sham
Device
Lead sponsor
Aerin Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
13
States / cities
Roseville, California • Torrance, California • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 25, 2026, 7:28 AM EDT
Recruiting Phase 2 Interventional

Further MT for Antibiotic-Resistant Bacterial Colonization

NCT05835206
View directory record Official record
Conditions
Intestinal Multi-drug Resistant Organism Colonization
Interventions
Microbiome Therapeutic, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

NCT03775278
View directory record Official record
Conditions
Otherwise Healthy Overweight or Obese
Interventions
PHP-303, Placebo
Drug · Other
Lead sponsor
pH Pharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption

NCT03270085
View directory record Official record
Conditions
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
Interventions
Colesevelam, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 25, 2026, 7:28 AM EDT
Completed No phase listed Observational

Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures

NCT02605343
View directory record Official record
Conditions
Acute Pain, Surgery
Interventions
NeuroIDgenetix Test Panel
Other
Lead sponsor
AltheaDx
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 25, 2026, 7:28 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

NCT03025698
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Eltrombopag, hATG, CsA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Serine and Fenofibrate Study in Patients With MacTel Type 2

NCT04907084
View directory record Official record
Conditions
Macular Telangiectasia Type 2
Interventions
Serine, Fenofibrate
Dietary Supplement · Drug
Lead sponsor
The Lowy Medical Research Institute Limited
Other
Eligibility
21 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)

NCT01947738
View directory record Official record
Conditions
Healthy
Interventions
VBY-891, Placebo
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

NCT03518138
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
Q-122, Placebo
Drug
Lead sponsor
Que Oncology
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Woodstock, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of a Tobacco Control Intervention in African-American Families

NCT01164306
View directory record Official record
Conditions
Tobacco Prevention, Environmental Tobacco Smoke Exposure, Tobacco Cessation
Interventions
LifeSkills Training, Healthy Lifestyle Behavior Choices, NRT and Motivational Interviewing (MI)
Behavioral
Lead sponsor
Augusta University
Other
Eligibility
8 Years and older
Enrollment
688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 25, 2026, 7:28 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Radicle Women's Sexual HealthTM CIX: A Study Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes

NCT07835763
View directory record Official record
Conditions
Sexual Desire
Interventions
Active Sexual Health Product 1, Active Sexual Health Product 2, Active Sexual Health Product 3, Placebo Sexual Health Control Product
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

NCT02627963
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Tivozanib hydrochloride, Sorafenib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 25, 2026, 7:28 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

NCT04597372
View directory record Official record
Conditions
Urinary Retention Postoperative
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older · Female only
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2Phase 3 Interventional

Blended Collaborative Care for Heart Failure and Co-Morbid Depression

NCT02044211
View directory record Official record
Conditions
Heart Failure, Systolic, Depression, Cardiovascular Disease
Interventions
Collaborative Care for Heart Failure, Collaborative Care for Depression
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 1 Interventional Results available

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

NCT02152007
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
1% sirolimus cream (TD201 1%)
Drug
Lead sponsor
TransDerm, Inc.
Industry
Eligibility
16 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Losartan for Patients With COVID-19 Requiring Hospitalization

NCT04312009
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

NCT03237481
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 25, 2026, 7:28 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

NCT00143611
View directory record Official record
Conditions
Sepsis
Interventions
Resatorvid, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 25, 2026, 7:28 AM EDT